Gilead’s $4.3B Bet on CymaBay’s Liver Drug by Mark Eisenberg 12.02.2024 Gilead Sciences plans to acquire CymaBay Therapeutics for $4.3 billion, expanding their liver disease portfolio. The deal is expected to ...
FDA Approves Takeda’s EoE Therapy EOHILIA by Lilu Anderson 12.02.2024 FDA approves Takeda's EOHILIA as first-line treatment for Eosinophilic Esophagitis. Groundbreaking oral therapy offers hope for improved quality of life.
Tonix Pharma’s Potential PTSD Cure: A Game-Changer? by Mark Eisenberg 12.02.2024 Tonix Pharmaceuticals receives FDA clearance for its OASIS trial, evaluating the efficacy of TNX-102 SL in treating acute stress reactions ...
AN2 Therapeutics Pauses Trial: Efficacy Concerns Rise by Mark Eisenberg 12.02.2024 AN2 Therapeutics voluntarily pauses enrollment in its epetraborole clinical trial due to lower efficacy. Safety is not a concern. The ...
Unlearn Receives Funding for Clinical Trial Digital Twin Tech by Lilu Anderson 09.02.2024 AI company Unlearn has secured $50m in funding to develop AI solutions that create digital twins for trial participants, helping ...